Skip to main content

Generics

  • GPhA outlines 2014 priorities

    WASHINGTON — The Generic Pharmaceutical Association on Monday identified its key priorities for 2014 — guarding against confusion a proposed labeling change would cause; gaining access to biosimilar generics; and heralding the cost savings generated by generic utilization. 

  • Endo Health Solutions completes Boca Pharmacal acquisition

    MALVERN, Penn. — Endo Health Solutions on Monday announced that its Qualitest subsidiary has completed the acquisition of privately-held Boca Pharmacal, a specialty pharmaceutical company, for approximately $225 million in cash.  

    Boca Pharmacal is a specialty generics company that focuses on niche areas, commercializing and developing products in categories that include controlled substances, semisolids and solutions.  

  • Report: Hospitals show renewed interest in on-campus retail pharmacies

    NEW YORK — A desire to provide an integrated continuum of care that leads to improved outcomes and patient satisfaction has placed a renewed focus on U.S. hospitals offering on-campus retail pharmacies, according to a report by HealthLeaders Media.

  • Study: One-third of chronically ill have trouble affording medicines, food

    TUCSON, Ariz. — Approximately 1-in-3 chronically-ill National Health Interview Survey participants are unable to afford food, medications or both, according to a study published Jan. 21 in the American Journal of Medicine. WIC and public health insurance participation are associated with less food insecurity and cost-related medication underuse.

  • Mylan launches world's first trastuzumab biosimilar

    MUMBAI and PITTSBURGH — Mylan on Monday announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India. The product — which will be marketed by Mylan as Hertraz — is used for the treatment of HER2-positive metastatic breast cancer. Hertraz is a biosimilar to Roche's Herceptin and is available in two strengths:  440mg and 150mg.

  • FDA re-examining risk profile of FDA-approved testosterone products

    SILVER SPRING, Md. — The Food and Drug Administration is investigating the risk of stroke, heart attack and death in men taking FDA-approved testosterone products, the agency announced Friday. 

  • Walgreens offers free blood-pressure testing in support of American Heart Month

    DEERFIELD, Ill. — In support of American Heart Month, Walgreens is offering free blood-pressure testing at all of its pharmacies and Healthcare Clinics throughout the month of February, the retailer announced Monday.

  • GPhA pays homage to retiring Rep. Henry Waxman

    WASHINGTON — Following the announcement that Rep. Henry Waxman, D-Calif., intended to retire, the Generic Pharmaceutical Association on Thursday bid adieu to a legislator who had a tremendous positive impact on the generic industry. 

X
This ad will auto-close in 10 seconds